Figure 3. Imaging disease progression in humans.

¹⁸F-FDG-PET/CT scan from a patient with pulmonary TB at the time when therapy was initiated (left panels) and 2 months after treatment has begun (right panels). Below are two matched axial CT slices from the area indicated by the plane on the left taken from the same scans. FDG is primarily a marker of increased tissue metabolism such as inflammation while the CT shows the structural abnormalities within this patient's lungs. Both sets of images illustrate the wide range of lesion types occupied by Mtb during infection that show differential kinetics of response to chemotherapy.